Read the following email: Dear Dr. Jones,

Our pharmaceutical company now received 47 complaints about the new pain reliever NoPain, created in your lab. Of the 47 complaints, 24 said their headache got worse, 15 said they had severe cramping after taking the medication, and 8 said they had both problems. We have only been distributing this pain reliever for about 30 days and we are very concerned. It has cost our company roughly 1.2 million dollars to create the drug and we have recorded sales of $98,600 in the past month at $10 a bottle, so that is 9,860 bottles. Should we be concerned? Do you think we should pull the product and conduct more research? We may end up losing money on this if we pursue this course of action. Should we keep the product on the shelves and secretly do more research? Or should we just do nothing for the time being, wait it out, and see what happens? Please get back to us as soon as possible with your recommendation.

Thank you,

Jane Smith

Head of Customer Relations

findings regarding similar problems in the market

Apatient who is 38 years of age is diagnosed with autosomal dominant polycystic kidney disease, a hereditary disease that results in fluid-filled cysts occupying space in the kidneys. the cysts can interfere with the function of the kidney and may burst and cause bleeding inside the kidney. the patient with polycystic kidney disease may or may not have a berry aneurysm of a blood vesseel in the brain that could lead to bleeding and death, cysts on the ovaries, and a mitral valve prolapse (in females) that can lead to dysrhythmias (irregular heart rhythms), or diverticula (outpouching of the bowel) that are susceptible to infection and inflammation and may lead to gastrointestinal bleeding. the patient is susceptible to retaining fluid in the abdomen so the abdomen is large to constipation, and to hypertension. there is no cure for the disease. the patient receives supportive care for the various symptoms or complications the patient may have. a. when explaining to the patient and the family about polycystic kidney disease, the nurse should explain what characteristics about an autosomal dominant genetic disease? b. how does variable expression of genetic characteristics play a role in the course of polycystic kidney disease and how can the nurse further predict the level of the disease? c. identify the roles of the nurse in integrating genetics in the nursing care provided for the patient.